Literature DB >> 16009958

Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.

Jean-François Bosset1, Gilles Calais, Laurent Mineur, Philippe Maingon, Ljiljana Radosevic-Jelic, Alain Daban, Etienne Bardet, Alexander Beny, Antoine Briffaux, Laurence Collette.   

Abstract

PURPOSE: The European Organisation for Research and Treatment of Cancer (EORTC) trial evaluated the addition of chemotherapy (CT) to preoperative radiation (preop RT) and the value of postoperative CT for improving the survival in patients with T3-4 resectable rectal cancer. Patients were allocated to the following four arms: arm 1, preop RT 45 Gy in 5 weeks; arm 2, preop RT plus two 5-day CT courses (fluorouracil 350 mg/m2/d and leucovorin 20 mg/m2/d) in the first and fifth week of RT; arm 3, preop RT plus four postoperative CT courses; and arm 4, preop RT and CT plus postoperative CT. We investigated the effect of adding CT on the pathologic parameters. PATIENTS AND METHODS: One thousand eleven patients were entered onto the trial; 505 received preop RT (arms 1 and 3), and 506 received preop RT-CT (arms 2 and 4). We analyzed the differences in tumor size, tumor node stage, number of retrieved nodes, and histologic features such as lymphatic, venous, and perineural invasions, tumor differentiation, and tumor type.
RESULTS: After preop RT-CT, tumors were smaller (P < .0001), had less advanced pT (P < .001) and pN stages (P < .001), had small numbers of examined nodes (P = .046), and less frequent LVN invasions (P < or = .008). Mucinous tumors increased after preop RT-CT (P < .001).
CONCLUSION: In patients with rectal cancer, preliminary results of EORTC Trial 22921 indicate that the addition of CT to preop RT induces down-sizing, downstaging, and significant changes in histologic characteristics. Longer follow-up is needed to assess the impact on local control and survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16009958     DOI: 10.1200/JCO.2005.02.113

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  148 in total

1.  Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case.

Authors:  Yoshiro Itatani; Takashi Akiyoshi; Hiroya Kuroyanagi; Keiko Yamakawa; Rota Noaki; Tsuyoshi Konishi; Yoshiya Fujimoto; Masashi Ueno; Masatoshi Oya; Mitsukuni Suenaga; Toshiharu Yamaguchi
Journal:  Surg Today       Date:  2011-11-12       Impact factor: 2.549

2.  Reconstruction of the irradiated extended abdominoperineal excision (APE) defect for locally advanced colorectal cancer.

Authors:  Mark A Boccola; Warren Matthew Rozen; Edmund W Ek; Damien Grinsell; Matthew A Croxford
Journal:  J Gastrointest Cancer       Date:  2011-03

3.  Colorectal Cancer OncoGuia.

Authors:  Paula Manchon Walsh; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

4.  The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.

Authors:  Rob Glynne-Jones; Maher Hadaki; Mark Harrison
Journal:  J Gastrointest Oncol       Date:  2013-09

5.  The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy.

Authors:  Daniel H Ahn; Christina Wu; Lai Wei; Terence M Williams; Evan Wuthrick; Sherif Abdel-Misih; Alan Harzman; Syed Husain; Carl Schmidt; Richard M Goldberg; Tanios Bekaii-Saab
Journal:  Am J Clin Oncol       Date:  2017-12       Impact factor: 2.339

Review 6.  Mucinous carcinoma of the rectum: a distinct clinicopathological entity.

Authors:  M Chand; S Yu; R I Swift; G Brown
Journal:  Tech Coloproctol       Date:  2013-12-11       Impact factor: 3.781

7.  Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer.

Authors:  Deniz Tural; Fatih Selcukbiricik; Özcan Yıldız; Olgun Elcin; Sibel Erdamar; Sabri Güney; Fuat Demireli; Evin Büyükünal; Süheyla Serdengeçti
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

8.  Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy.

Authors:  Ming-Jen Sheu; Chien-Feng Li; Ching-Yih Lin; Sung-Wei Lee; Li-Ching Lin; Tzu-Ju Chen; Li-Jung Ma
Journal:  Tumour Biol       Date:  2014-05-09

Review 9.  Advances and challenges in treatment of locally advanced rectal cancer.

Authors:  J Joshua Smith; Julio Garcia-Aguilar
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

10.  Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

Authors:  Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.